Crizotinib

• 产品号: PZ0191
• CAS号: 877399-52-5
• 分子式: C21H22Cl2FN5O
• 分子量: 450.3366832
• 纯 度: ≥98% (HPLC)

产品别名

• 标题: Crizotinib
• IUPAC标准名: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine
• IUPAC传统名: crizotinib
• 别名: PF02341066; (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; PF 2341066; PF-02341066; Xalkori

产品登记号

• CAS号: 877399-52-5
• MDL号: MFCD12407409

产品性质

• Empirical Formula (Hill Notation): C21H22Cl2FN5O
• 纯度: ≥98% (HPLC)
• 外观: white to tan powder
• 保存温度: room temp

产品详细信息

详细说明 (简体中文)

Legal Information
Sold for research purposes under agreement from Pfizer Inc.
Biochem/physiol Actions
Crizotinib (PF-02341066) is an ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor) and anaplastic lymphoma kinase (ALK). It is a highly specific inhibitor of c-Met and ALK among > 120 different RTKs surveyed. Crizotinib was recently approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.